Sequential radiofrequency ablation and surgical debulking for unresectable colorectal carcinoma: Thermo-surgical ablation
Background and Objectives Despite decreasing frequency, local recurrences of unresectable colorectal cancer (CRC) remain difficult problems. These patients have few treatment options with conventional therapy. Preliminary results of sequential radiofrequency ablation (RFA) and surgical debulking (th...
Gespeichert in:
Veröffentlicht in: | Journal of surgical oncology 2013-02, Vol.107 (2), p.144-147 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background and Objectives
Despite decreasing frequency, local recurrences of unresectable colorectal cancer (CRC) remain difficult problems. These patients have few treatment options with conventional therapy. Preliminary results of sequential radiofrequency ablation (RFA) and surgical debulking (thermo‐surgical ablation) suggest this technique may have benefit.
Methods
We reviewed a prospective database of patients undergoing thermo‐surgical ablation for unresectable colorectal carcinoma from 2003 to 2011.
Results
Sixteen patients were treated with unresectable, recurrent abdomino‐pelvic colorectal carcinoma: 11 in pelvis; 4 with isolated aortic/retroperitoneal disease; and 1 with pelvic and peri‐adrenal/retroperitoneal disease. Eleven patients had recurrent rectal cancer and five had recurrent colon cancer.
Median overall and 3‐year actuarial survivals were 15 months and 24%, respectively. Median and 3‐year PFS was 12 months and 19%, respectively. Three patients without disease have survived 0.75, 4.0, and 7.0 years. Two patients died at 5.0 and 5.5 years. A disease‐free interval (DFI) of >24 months after initial resection was associated with longer overall survival (60 months vs. 4 months; P = 0.001).
Conclusions
Thermo‐surgical debulking appears to have a role in the treatment of some patients with recurrent, unresectable CRC; those patients with DFI >24 months after initial surgery benefited the most. J. Surg. Oncol. 2013;107:144–147. © 2012 Wiley Periodicals, Inc. |
---|---|
ISSN: | 0022-4790 1096-9098 |
DOI: | 10.1002/jso.23211 |